xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06010173</url>
    </required_header>
    <id_info>
      <org_study_id>GDX-44-014 - GDX-101</org_study_id>
      <nct_id>NCT06010173</nct_id>
    </id_info>
    <brief_title>Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children</brief_title>
    <official_title>Efficacy and Safety of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Guerbet</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Bracco Imaging S.p.A.</agency>
        <agency_class>Industry</agency_class>
      </collaborator>
    </sponsors>
    <source>Guerbet</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This trial conducted in Japan includes 2 different cohorts of patients: adult patients and&#xD;
        pediatric patients with two different designs.&#xD;
  &#xD;
          -  The cohort of adult patients has a prospective, multi-center, randomized, double-blind,&#xD;
             controlled, and cross-over design.&#xD;
  &#xD;
          -  The cohort of pediatric patients has a prospective, multi-center, non-randomized,&#xD;
             open-label and single arm design.&#xD;
  &#xD;
        Primary objective to demonstrate the non-inferiority of gadopiclenol-enhanced MRI at 0.05&#xD;
        mmol/kg body weight (BW) compared to gadobutrol-enhanced MRI at 0.1 mmol/kg BW in terms of&#xD;
        lesion visualization is applicable for adult patients referred for contrast-enhanced MRI of&#xD;
        Central Nervous System (CNS) or Body regions.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Adult cohort:&#xD;
  &#xD;
        The trial includes a maximum of 5 visits and the record of patient's diagnosis as standard of&#xD;
        truth:&#xD;
  &#xD;
          -  One screening visit (V1) up to 7 days prior to the imaging visit (V2) (V1 can be done on&#xD;
             the same day as V2 if all the inclusion/non-inclusion criteria are met).&#xD;
  &#xD;
          -  Two sequential imaging visits (V2 and V4, minimum interval 2 days and up to 14 days):&#xD;
             each visit will consist of gadopiclenol injection or comparator injection and MRI&#xD;
             procedure.&#xD;
  &#xD;
          -  Two safety visits (V3 and V5): 1 day after each injection and MRI examination.&#xD;
  &#xD;
        Pediatric cohort:&#xD;
  &#xD;
        The inclusions will be divided into 4 age groups: patients from birth to 23 months of age&#xD;
        inclusive, patients from 2 to 6 years, patients from 7 to 11 years and patients from 12 to 17&#xD;
        years. The recruitment in the 3 older groups of pediatric patients can be conducted in&#xD;
        parallel with adult patients' enrolment. The decision to start the inclusion in the group of&#xD;
        patients aged from birth to 23 months will be taken by the Trial Safety Review Board (TSRB).&#xD;
  &#xD;
        The trial includes a maximum of 3 visits and the record of patient's diagnosis as standard of&#xD;
        truth:&#xD;
  &#xD;
          -  One screening visit (V1) up to 7 days prior to the imaging visit (V2) (V1 can be done on&#xD;
             the same day as V2 if all the inclusion/non-inclusion criteria are met).&#xD;
  &#xD;
          -  One imaging visit (V2): will consist of gadopiclenol injection and MRI procedure.&#xD;
  &#xD;
          -  pharmacokinetics (PK) group: Blood sampling for PK will start after gadopiclenol&#xD;
             injection according to defined blood sampling schedule and will take up to 8 hours.&#xD;
  &#xD;
          -  One safety visit (V3): 1 day after gadopiclenol injection and MRI examination.&#xD;
  &#xD;
        All Patients:&#xD;
  &#xD;
        Images will be assessed off-site in a centralized manner.&#xD;
  &#xD;
        Pediatric group :&#xD;
  &#xD;
        24 patients of the pediatric cohort will be included in gadopiclenol PK profile assessment.&#xD;
  &#xD;
        The approach implemented for pharmacokinetics (PK) analyses allows sparse blood sampling only&#xD;
        and is selected to minimize the clinical burden to children.&#xD;
  &#xD;
        All cohorts :&#xD;
  &#xD;
        During the trial, the safety of the patients will be monitored and assessed based on the&#xD;
        reporting of adverse events (AEs), including vital signs, ECG for pediatric patients and&#xD;
        clinical laboratory parameters (blood samples).&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">July 21, 2023</start_date>
    <completion_date type="Anticipated">December 2024</completion_date>
    <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
    <phase>Phase 3</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Crossover Assignment</intervention_model>
      <primary_purpose>Diagnostic</primary_purpose>
      <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Lesion visualization on Paired Images: border delineation</measure>
      <time_frame>MRI central reading within 2 days to 2 weeks after each MRI exam</time_frame>
      <description>The lesion visualization criterion is based on 3 co-primary criteria rated on a scale from 1 to 4 : border delineation, internal morphology and degree of contrast enhancement assessed by 3 independent off-site blinded readers (IBR).&#xD;
  The IBR will record each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with comparator.&#xD;
  Delineation of the lesion border is defined as the distinction of lesion from surrounding tissues, structures, or edema, and the detection of extent of the lesion. This criterion will be assessed through the following scale:&#xD;
  = None&#xD;
  = Moderate&#xD;
  = Good&#xD;
  = Excellent&#xD;
  For each co-primary criterion, a mean of scores will be calculated and will range from 1 to 4.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Lesion visualization on Paired Images: internal morphology</measure>
      <time_frame>MRI central reading within 2 days to 2 weeks after each MRI exam</time_frame>
      <description>The lesion visualization criterion is based on 3 co-primary criteria rated on a scale from 1 (Poor) to 4 (Excellent): border delineation, internal morphology and degree of contrast enhancement assessed by 3 independent off-site blinded readers (IBR).&#xD;
  The IBR will record each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with comparator.&#xD;
  Internal morphology of the lesion includes an identification of lesion architecture and the intra-lesion features such as necrosis, hemorrhage, and vascularity. This criterion will be assessed through the following scale:&#xD;
  = Poor&#xD;
  = Moderate&#xD;
  = Good&#xD;
  = Excellent&#xD;
  For each co-primary criterion, a mean of scores will be calculated and will range from 1 to 4.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Lesion visualization on Paired Images: degree of contrast enhancement</measure>
      <time_frame>MRI central reading within 2 days to 2 weeks after each MRI exam</time_frame>
      <description>The lesion visualization criterion is based on 3 co-primary criteria rated on a scale from 1 (Poor) to 4 (Excellent): border delineation, internal morphology and degree of contrast enhancement assessed by 3 independent off-site blinded readers (IBR).&#xD;
  The IBR will record each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with comparator.&#xD;
  This criterion will be a qualitative assessment (not based on signal intensity measurement) according to the following scale:&#xD;
  = No&#xD;
  = Moderate&#xD;
  = Good&#xD;
  = Excellent&#xD;
  For each co-primary criterion, a mean of scores will be calculated and will range from 1 to 4.</description>
    </primary_outcome>
    <number_of_arms>3</number_of_arms>
    <enrollment type="Anticipated">240</enrollment>
    <condition>Lesion in Body Region</condition>
    <condition>CNS Lesion</condition>
    <arm_group>
      <arm_group_label>Adult cohort</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Each of 2 MRI visits will consist of gadopiclenol injection or comparator injection and MRI procedure (administered in a randomized, blinded and cross-over design). Gadopiclenol and comparator will be injected as a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. The injection rate should be identical for both products and may vary depending on scanned organ/region and age of patients.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Pediatric cohort</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Pediatric patients will undergo one MRI examination with gadopiclenol (V2). Gadopiclenol will be injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Pediatric PK cohort</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Pediatric patients will undergo one MRI examination with gadopiclenol (V2). Gadopiclenol will be injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. In addition a total of 3 blood samples per patient will be taken post-injection for PK analysis over the period of 8 hours post-injection.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Gadopiclenol</intervention_name>
      <description>Dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.05 mmol/kg BW</description>
      <arm_group_label>Adult cohort</arm_group_label>
      <arm_group_label>Pediatric PK cohort</arm_group_label>
      <arm_group_label>Pediatric cohort</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Comparator</intervention_name>
      <description>Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW</description>
      <arm_group_label>Adult cohort</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Inclusion criteria for all patients:&#xD;
  &#xD;
                 1. All Patient presenting with known or suspected enhancing abnormality(ies) and/or&#xD;
                    lesion(s) in CNS or in at least one body region among head &amp; neck, thorax (e.g.&#xD;
                    breast), abdomen (e.g. liver, pancreas and kidney), pelvis (e.g. uterus, ovary&#xD;
                    and prostate) and musculoskeletal (e.g. extremities) based on a previous imaging&#xD;
                    procedure performed within 12 months prior to Informed Consent Form (ICF)&#xD;
                    signature.&#xD;
  &#xD;
                 2. All If the patient was treated (either with radiation, surgery, biopsy, or other&#xD;
                    relevant treatments) between previous imaging evaluation and trial MRI, there&#xD;
                    should still be a high suspicion of remaining enhancing abnormality(ies) and/or&#xD;
                    lesion(s) based on available clinical information.&#xD;
  &#xD;
                 3. All Patient able and willing to participate in the trial.&#xD;
  &#xD;
                 4. All Patient affiliated to national health insurance according to local regulatory&#xD;
                    requirements.&#xD;
  &#xD;
            -  Inclusion criteria for adult patients:&#xD;
  &#xD;
                 1. A Female or male adult patient having reached legal majority age of 18 years.&#xD;
  &#xD;
                 2. A Patient scheduled for a contrast-enhanced MRI examination of CNS or a Body&#xD;
                    region for clinical reasons and agreeing to have a second contrast-enhanced MRI&#xD;
                    examination for the purpose of the trial.&#xD;
  &#xD;
                 3. A Patient having read the information and having provided his/her consent to&#xD;
                    participate in writing by dating and signing the informed consent prior to any&#xD;
                    trial related procedure being conducted.&#xD;
  &#xD;
            -  Inclusion criteria for pediatric patients:&#xD;
  &#xD;
                 1. P Female or male pediatric patient from birth to 17 years. For patients aged from&#xD;
                    birth to 27 days, only term newborn infants are eligible.&#xD;
  &#xD;
                    Patients may not have reached the age of 18 years at the MRI examination.&#xD;
  &#xD;
                 2. P Patient whose parent(s) or legal guardian (where applicable) having read the&#xD;
                    information provided his/her/their consent to patient's participation in writing&#xD;
                    by dating and signing the informed consent prior to any trial related procedure&#xD;
                    being conducted.&#xD;
  &#xD;
                 3. P Patient with capacity of understanding who received age- and&#xD;
                    maturity-appropriate information and provided his/her assent to participate in&#xD;
                    the trial.&#xD;
  &#xD;
                 4. P-PK Patient and his/her parent(s) or legal guardian (where applicable) having&#xD;
                    read the information and provided his/her consent in writing by dating and&#xD;
                    signing the Informed Consent form or respectively in the patient assent form&#xD;
                    their consent to participate in the PK analyses.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Non-inclusion criteria for all patients:&#xD;
  &#xD;
                 1. All Patient referred for contrast-enhanced cardiac MRI as primary examination.&#xD;
  &#xD;
                 2. All Patient having received any investigational medicinal product (IMP) within 7&#xD;
                    days prior to trial entry or scheduled to receive any investigational treatment&#xD;
                    during the trial.&#xD;
  &#xD;
                 3. All Patient presenting with any contraindication to MRI examinations.&#xD;
  &#xD;
                 4. All Patient having received any contrast agent (for MRI or CT) within 3 days (or&#xD;
                    7 days for patients &lt;1 year old) prior to trial product administration or&#xD;
                    scheduled to receive any contrast agent during the trial or within 24 hours after&#xD;
                    the last trial product administration (or 7 days after for patients &lt;1 year old).&#xD;
  &#xD;
                 5. All Patient with anticipated, current, or past condition (medical, psychological,&#xD;
                    social or geographical) that would compromise the patient's safety or her/his&#xD;
                    ability to participate in the trial in the Investigator's opinion.&#xD;
  &#xD;
                 6. All Female patient of childbearing potential with a positive urine pregnancy test&#xD;
                    done within 1 day prior to each contrast agent administration and not able / not&#xD;
                    willing to use highly effective birth-controlled method during the trial&#xD;
                    duration.&#xD;
  &#xD;
                    Female must have effective medically approved contraception until the last trial&#xD;
                    visit, if of childbearing potential or with amenorrhea for less than 12 months or&#xD;
                    must be surgically sterilized or post-menopausal (&gt; 2 years amenorrhea).&#xD;
  &#xD;
                 7. All Patient unlikely to comply with the protocol, e.g., uncooperative attitude,&#xD;
                    inability to return for follow-up visits and/or unlikelihood of completing the&#xD;
                    trial.&#xD;
  &#xD;
                 8. All Patient related to the Investigator or any other trial staff or relative&#xD;
                    directly involved in the trial conduct.&#xD;
  &#xD;
                 9. All Patient with known contra-indication(s) to the use or with known sensitivity&#xD;
                    to one of the products under investigation or to other gadolinium based contrast&#xD;
                    agents (GBCAs) (such as hypersensitivity, post contrast acute kidney injury).&#xD;
  &#xD;
            -  Non-inclusion criteria for adult patients:&#xD;
  &#xD;
                 1. A Patient with acute disease that may rapidly evolve between the 2 MRI&#xD;
                    examinations&#xD;
  &#xD;
                 2. A Patient previously randomized in this trial.&#xD;
  &#xD;
                 3. A Patient expected/scheduled to have any treatment or medical procedure (e.g.,&#xD;
                    chemotherapy, radiotherapy, biopsy, or surgery etc.) that may impact the aspects&#xD;
                    of the imaged lesions between the 2 MRI examinations. (Patients under&#xD;
                    corticosteroids and/or maintenance chemotherapy with a stable dose at the time of&#xD;
                    screening visit and throughout the trial can be included).&#xD;
  &#xD;
                 4. A Patient presenting an estimated Glomerular Filtration Rate (eGFR) &lt; 30&#xD;
                    mL/min/1.73 m^2 (based on Japanese coefficient-modified CKD-EPI (Chronic Kidney&#xD;
                    Disease - Epidemiology Collaboration) formula) assessed within 1 week prior to&#xD;
                    each contrast agent administration.&#xD;
  &#xD;
            -  Non-inclusion criteria for pediatric patients:&#xD;
  &#xD;
                 1. P Patient with previously attributed IMP number in this trial.&#xD;
  &#xD;
                 2. P Patient with known long QT syndrome.&#xD;
  &#xD;
                 3. P Patient presenting an estimated Glomerular Filtration Rate (eGFR) outside&#xD;
                    age-adjusted normal ranges (based on bedside Schwartz equation) assessed within&#xD;
                    one week prior to contrast agent administration.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>N/A</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Toshiaki Taoka, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Nagoya University, JAPAN</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Anna Grinberg</last_name>
      <phone>+33145915000</phone>
      <phone_ext>+33</phone_ext>
      <email>anna.grinberg@guerbet.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Audrey Sahns</last_name>
      <phone>609-514-2200</phone>
      <email>audrey.sahns@diag.bracco.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Meitetsu Hospital</name>
        <address>
          <city>Aichi</city>
          <zip>451-8511</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Hidemori Araki</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Fukuoka University Hospital</name>
        <address>
          <city>Fukuoka</city>
          <zip>814-0180</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Kengo Yoshimitsu</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Gifu University Hospital</name>
        <address>
          <city>Gifu</city>
          <zip>501-1194</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Masayuki Matsuo</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Gunma University Hospital</name>
        <address>
          <city>Gunma</city>
          <zip>371-8511</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Yoshito Tsushima</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Hiroshima City Hiroshima Citizens Hospital</name>
        <address>
          <city>Hiroshima</city>
          <zip>730-8518</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Akihisa Tamura</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Nakamura Memorial Hospital</name>
        <address>
          <city>Hokkaido</city>
          <zip>060-8570</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Kenichi Sato</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>National Hospital Organization Shikoku Medical Center for Children and Adults</name>
        <address>
          <city>Kagawa</city>
          <zip>765-8507</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Tsuyoshi Imai</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Kanagawa Children's Medical Center</name>
        <address>
          <city>Kanagawa</city>
          <zip>232-0066</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Emiko Miura</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Kobe City Medical Center General Hospital</name>
        <address>
          <city>Kobe</city>
          <zip>650-0047</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Kumiko Ando</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>University Hospital, Kyoto Prefectural University of Medicine</name>
        <address>
          <city>Kyoto</city>
          <zip>602-8566</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Kei Yamada</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Kyoto City Hospital</name>
        <address>
          <city>Kyoto</city>
          <zip>604-8845</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Ryo Miyahara</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Tohoku University Hospital</name>
        <address>
          <city>Miyagi</city>
          <zip>980-8574</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Hideki Ota</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Nara Medical University Hospital</name>
        <address>
          <city>Nara</city>
          <zip>634-8522</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Toshihiro Tanaka</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Kawasaki Medical School Hospital</name>
        <address>
          <city>Okayama</city>
          <zip>701-0192</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Tsutomu Tamada</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Osaka Metropolitan University Hospital</name>
        <address>
          <city>Osaka</city>
          <zip>545-8586</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Yukio Miki</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Tominaga Hospital</name>
        <address>
          <city>Osaka</city>
          <zip>556-0017</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Yoshiyasu Iwai</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Takatsuki General Hospital</name>
        <address>
          <city>Osaka</city>
          <zip>569-1192</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Satoru Takahashi</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Saitama Prefectural Children's Medical Center</name>
        <address>
          <city>Saitama</city>
          <zip>330-8777</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Katsuyoshi Koh</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Shin-Kuki General Hospital</name>
        <address>
          <city>Saitama</city>
          <zip>346-0021</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Hirohiko Arimoto</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Shizuoka General Hospital</name>
        <address>
          <city>Shizuoka</city>
          <zip>420-8527</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Kazuya Ohno</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Hamamatsu University Hospital</name>
        <address>
          <city>Shizuoka</city>
          <zip>431-3192</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Satoshi Goshima</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Jichi Medical University Hospital</name>
        <address>
          <city>Tochigi</city>
          <zip>329-0498</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Kensuke Kawai</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Tokyo Shinagawa Hospital</name>
        <address>
          <city>Tokyo</city>
          <zip>140-8522</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Masaharu Shinkai</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Toho University Omori Medical Center</name>
        <address>
          <city>Tokyo</city>
          <zip>143-8541</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Masaaki Hori</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>National Center for Child Health and Development</name>
        <address>
          <city>Tokyo</city>
          <zip>157-8535</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Shunsuke Nosaka</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Tokyo Metropolitan Children's Medical Center</name>
        <address>
          <city>Tokyo</city>
          <zip>183-8561</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Yuki Yuza</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Kurobe City Hospital</name>
        <address>
          <city>Toyama</city>
          <zip>938-8502</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Itsuro Terada</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Yamaguchi University Hospital</name>
        <address>
          <city>Yamaguchi</city>
          <zip>755-8505</zip>
          <country>Japan</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Masahiro Tanabe</last_name>
      </contact>
    </location>
    <location_countries>
      <country>Japan</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>July 28, 2023</study_first_submitted>
    <study_first_submitted_qc>August 17, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 24, 2023</study_first_posted>
    <last_update_submitted>August 28, 2023</last_update_submitted>
    <last_update_submitted_qc>August 28, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 31, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06010173
  org study id: GDX-44-014 - GDX-101
  nct id: NCT06010173
  lead sponsor: 
  collaborator: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  This trial conducted in Japan includes 2 different cohorts of patients: adult patients and
        pediatric patients with two different designs.
  
          -  The cohort of adult patients has a prospective, multi-center, randomized, double-blind,
             controlled, and cross-over design.
  
          -  The cohort of pediatric patients has a prospective, multi-center, non-randomized,
             open-label and single arm design.
  
        Primary objective to demonstrate the non-inferiority of gadopiclenol-enhanced MRI at 0.05
        mmol/kg body weight (BW) compared to gadobutrol-enhanced MRI at 0.1 mmol/kg BW in terms of
        lesion visualization is applicable for adult patients referred for contrast-enhanced MRI of
        Central Nervous System (CNS) or Body regions.
  Adult cohort:
  
        The trial includes a maximum of 5 visits and the record of patient's diagnosis as standard of
        truth:
  
          -  One screening visit (V1) up to 7 days prior to the imaging visit (V2) (V1 can be done on
             the same day as V2 if all the inclusion/non-inclusion criteria are met).
  
          -  Two sequential imaging visits (V2 and V4, minimum interval 2 days and up to 14 days):
             each visit will consist of gadopiclenol injection or comparator injection and MRI
             procedure.
  
          -  Two safety visits (V3 and V5): 1 day after each injection and MRI examination.
  
        Pediatric cohort:
  
        The inclusions will be divided into 4 age groups: patients from birth to 23 months of age
        inclusive, patients from 2 to 6 years, patients from 7 to 11 years and patients from 12 to 17
        years. The recruitment in the 3 older groups of pediatric patients can be conducted in
        parallel with adult patients' enrolment. The decision to start the inclusion in the group of
        patients aged from birth to 23 months will be taken by the Trial Safety Review Board (TSRB).
  
        The trial includes a maximum of 3 visits and the record of patient's diagnosis as standard of
        truth:
  
          -  One screening visit (V1) up to 7 days prior to the imaging visit (V2) (V1 can be done on
             the same day as V2 if all the inclusion/non-inclusion criteria are met).
  
          -  One imaging visit (V2): will consist of gadopiclenol injection and MRI procedure.
  
          -  pharmacokinetics (PK) group: Blood sampling for PK will start after gadopiclenol
             injection according to defined blood sampling schedule and will take up to 8 hours.
  
          -  One safety visit (V3): 1 day after gadopiclenol injection and MRI examination.
  
        All Patients:
  
        Images will be assessed off-site in a centralized manner.
  
        Pediatric group :
  
        24 patients of the pediatric cohort will be included in gadopiclenol PK profile assessment.
  
        The approach implemented for pharmacokinetics (PK) analyses allows sparse blood sampling only
        and is selected to minimize the clinical burden to children.
  
        All cohorts :
  
        During the trial, the safety of the patients will be monitored and assessed based on the
        reporting of adverse events (AEs), including vital signs, ECG for pediatric patients and
        clinical laboratory parameters (blood samples).
  allocation: Randomized
  intervention model: Crossover Assignment
  primary purpose: Diagnostic
  masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  measure: Lesion visualization on Paired Images: border delineation
  time frame: MRI central reading within 2 days to 2 weeks after each MRI exam
  description: The lesion visualization criterion is based on 3 co-primary criteria rated on a scale from 1 to 4 : border delineation, internal morphology and degree of contrast enhancement assessed by 3 independent off-site blinded readers (IBR).
  The IBR will record each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with comparator.
  Delineation of the lesion border is defined as the distinction of lesion from surrounding tissues, structures, or edema, and the detection of extent of the lesion. This criterion will be assessed through the following scale:
  = None
  = Moderate
  = Good
  = Excellent
  For each co-primary criterion, a mean of scores will be calculated and will range from 1 to 4.
  measure: Lesion visualization on Paired Images: internal morphology
  time frame: MRI central reading within 2 days to 2 weeks after each MRI exam
  description: The lesion visualization criterion is based on 3 co-primary criteria rated on a scale from 1 (Poor) to 4 (Excellent): border delineation, internal morphology and degree of contrast enhancement assessed by 3 independent off-site blinded readers (IBR).
  The IBR will record each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with comparator.
  Internal morphology of the lesion includes an identification of lesion architecture and the intra-lesion features such as necrosis, hemorrhage, and vascularity. This criterion will be assessed through the following scale:
  = Poor
  = Moderate
  = Good
  = Excellent
  For each co-primary criterion, a mean of scores will be calculated and will range from 1 to 4.
  measure: Lesion visualization on Paired Images: degree of contrast enhancement
  time frame: MRI central reading within 2 days to 2 weeks after each MRI exam
  description: The lesion visualization criterion is based on 3 co-primary criteria rated on a scale from 1 (Poor) to 4 (Excellent): border delineation, internal morphology and degree of contrast enhancement assessed by 3 independent off-site blinded readers (IBR).
  The IBR will record each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with comparator.
  This criterion will be a qualitative assessment (not based on signal intensity measurement) according to the following scale:
  = No
  = Moderate
  = Good
  = Excellent
  For each co-primary criterion, a mean of scores will be calculated and will range from 1 to 4.
  arm group label: Adult cohort
  arm group type: Experimental
  description: Each of 2 MRI visits will consist of gadopiclenol injection or comparator injection and MRI procedure (administered in a randomized, blinded and cross-over design). Gadopiclenol and comparator will be injected as a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. The injection rate should be identical for both products and may vary depending on scanned organ/region and age of patients.
  arm group label: Pediatric cohort
  arm group type: Experimental
  description: Pediatric patients will undergo one MRI examination with gadopiclenol (V2). Gadopiclenol will be injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector.
  arm group label: Pediatric PK cohort
  arm group type: Experimental
  description: Pediatric patients will undergo one MRI examination with gadopiclenol (V2). Gadopiclenol will be injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. In addition a total of 3 blood samples per patient will be taken post-injection for PK analysis over the period of 8 hours post-injection.
  intervention type: Drug
  intervention name: Gadopiclenol
  description: Dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.05 mmol/kg BW
  arm group label: Adult cohort
  arm group label: Pediatric PK cohort
  arm group label: Pediatric cohort
  intervention type: Drug
  intervention name: Comparator
  description: Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW
  arm group label: Adult cohort
  criteria: 
  gender: All
  minimum age: N/A
  maximum age: N/A
  healthy volunteers: No
  last name: Toshiaki Taoka, MD
  role: Principal Investigator
  affiliation: Nagoya University, JAPAN
  last name: Anna Grinberg
  phone: +33145915000
  phone ext: +33
  email: anna.grinberg@guerbet.com
  last name: Audrey Sahns
  phone: 609-514-2200
  email: audrey.sahns@diag.bracco.com
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Not yet recruiting
  contact: 
  country: Japan
  responsible party type: Sponsor